porozendoОстеопороз и остеопатииOsteoporosis and Bone Diseases2072-26802311-0716Endocrinology Research Centre10.14341/osteo2010337-41porozendo-4195Research ArticleСтатьиArticlesПРИМЕНЕНИЕ ДЖЕНЕРИКОВ - СПОСОБ ПОВЫШЕНИЯ ПРИВЕРЖЕННОСТИ ЛЕЧЕНИЮ ОСТЕОПОРОЗАPRIMENENIE DZhENERIKOV - SPOSOB POVYShENIYa PRIVERZhENNOSTI LEChENIYu OSTEOPOROZASkripnikovaI A-RozhinskayaL Ya-201015122010133№3 (2010)3741Copyright © Skripnikova I.A., Rozhinskaya L.Y., 20102010Skripnikova I.A., Rozhinskaya L.Y.Skripnikova I.A., Rozhinskaya L.Y.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.osteo-endojournals.ru/jour/article/view/4195остеопороздженерикиэкономическая эффективностьФорозаReferencesЛесняк Ю.Ф. Анализ за- трат при профилактике перелома проксимального отдела бедра, ассоциированного с остеопо- розом. Остеопороз и остеопа- тии.2003. 3: 2-5.Лесняк Ю.Ф. Анализ за- трат при профилактике перелома проксимального отдела бедра, ассоциированного с остеопо- розом. Остеопороз и остеопа- тии.2003. 3: 2-5.Лялина В.В., Мылов Н.М., Дмитриева Е.Г. и др. Изуче- ние переносимости алендроната 70 мг в неделю и причин отмены лечения у больных постменопаузальным остеопорозом в условиях реальной клинической практики. Остеопороз и остеопатии. 2007. 3:31-35.Лялина В.В., Мылов Н.М., Дмитриева Е.Г. и др. Изуче- ние переносимости алендроната 70 мг в неделю и причин отмены лечения у больных постменопаузальным остеопорозом в условиях реальной клинической практики. Остеопороз и остеопатии. 2007. 3:31-35.Марченкова Л., Древаль А., Крюкова И., и др. Оценка медицинской помощи больным остеопорозом по результатам анкетирования врачей московской области. Врач. 2009.11: 95-102.Марченкова Л., Древаль А., Крюкова И., и др. Оценка медицинской помощи больным остеопорозом по результатам анкетирования врачей московской области. Врач. 2009.11: 95-102.Рожинская Л.Я., Дзеранова Л.К., Марова Е.И. и др. Ре- зультаты лечения постменопаузального остеопороза бисфосфонатом фосамаксом (алендронатом). Остеопороз и остеопатии. 1998. 2:28-32.Рожинская Л.Я., Дзеранова Л.К., Марова Е.И. и др. Ре- зультаты лечения постменопаузального остеопороза бисфосфонатом фосамаксом (алендронатом). Остеопороз и остеопатии. 1998. 2:28-32.Руководство по остеопорозу. Под ред. проф.Л.И.Беневоленской. БИНОМ . 2003.10-53.Руководство по остеопорозу. Под ред. проф.Л.И.Беневоленской. БИНОМ . 2003.10-53.Скрипникова И.А., Косматова О.В. Результаты лечения постменопаузального остеопороза бисфосфонатом фосамаксом. Остеопороз и остеопатии. 2004.1:16-19.Скрипникова И.А., Косматова О.В. Результаты лечения постменопаузального остеопороза бисфосфонатом фосамаксом. Остеопороз и остеопатии. 2004.1:16-19.Скрипникова И.А., Косматова О.В., Новиков В.Е. и др. Результаты открытого многоцентрового исследования эффективности и переносимости фосамакса 70 мг 1 раз в неделю при постменопаузальном остеопорозе. Остеопороз и остеопатии. 2005.3: 34-38.Скрипникова И.А., Косматова О.В., Новиков В.Е. и др. Результаты открытого многоцентрового исследования эффективности и переносимости фосамакса 70 мг 1 раз в неделю при постменопаузальном остеопорозе. Остеопороз и остеопатии. 2005.3: 34-38.Торопцова Н.В., Никитинская О.А., Демин Н.В. и др. Результаты изучения эффективности еженедельного приема алендроната (фосамакс® у больных с первичным остеопорозом. Остеопороз и остеопатии. 2006. 1:23-25.Торопцова Н.В., Никитинская О.А., Демин Н.В. и др. Результаты изучения эффективности еженедельного приема алендроната (фосамакс® у больных с первичным остеопорозом. Остеопороз и остеопатии. 2006. 1:23-25.Энциклопедический словарь терминов фармаколо- гии, фармакотерапии и фармации. Шварц Г.Я. -М.: Литтерра, 2008. -576 с.Энциклопедический словарь терминов фармаколо- гии, фармакотерапии и фармации. Шварц Г.Я. -М.: Литтерра, 2008. -576 с.Adami S., Baroni M.C., Broggini M., et al. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin. Osteoporosis Int. 1993. (Suppl 3):S21-27.Adami S., Baroni M.C., Broggini M., et al. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin. Osteoporosis Int. 1993. (Suppl 3):S21-27.Black D.M., Cummings S.R., Karpf D.B. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention Trial Research Group. Lancet. 1996.348: 1535-41.Black D.M., Cummings S.R., Karpf D.B. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention Trial Research Group. Lancet. 1996.348: 1535-41.Black D.M., Delmas P.D., Eastell R., et al. 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007. 356(18): 1809-22.Black D.M., Delmas P.D., Eastell R., et al. 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007. 356(18): 1809-22.Bock O., Felsenberg D. Bisphosphonates in the management of postmenopausal osteoporosis- optimizing efficacy in clinical practice. Clinical Interven Aging. 2008. 3(2):279-297.Bock O., Felsenberg D. Bisphosphonates in the management of postmenopausal osteoporosis- optimizing efficacy in clinical practice. Clinical Interven Aging. 2008. 3(2):279-297.Black D.M., Schwartz A.V., Ensrud K.E. et al. Effect of continuing or stopping alendronate after 5 years of treatment: The fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA. 2006. 296: 2927-38.Black D.M., Schwartz A.V., Ensrud K.E. et al. Effect of continuing or stopping alendronate after 5 years of treatment: The fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA. 2006. 296: 2927-38.Bonnen S., Laan R.F., Barton I.P., et al. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int. 2005. 16:1291-8.Bonnen S., Laan R.F., Barton I.P., et al. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int. 2005. 16:1291-8.Bone HG, Hosking D., Devogelaer J-P, et al.Ten years experience with Alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004.350: 1189-1199.Bone HG, Hosking D., Devogelaer J-P, et al.Ten years experience with Alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004.350: 1189-1199.Cranney A., Guyatt G., Griffith L. et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev.2002. 23(4): 570-578.Cranney A., Guyatt G., Griffith L. et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev.2002. 23(4): 570-578.Curtis J.R., Westfall A.O., Cheng H., et al. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101.038 new bisphosphonate users. J Bone Miner Res. 2008. 23(9): 1435-1441.Curtis J.R., Westfall A.O., Cheng H., et al. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101.038 new bisphosphonate users. J Bone Miner Res. 2008. 23(9): 1435-1441.Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention trial. JAMA.1998. 280:2077-82.Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention trial. JAMA.1998. 280:2077-82.Chesnut III C.H., Skag A., Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently of fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004. 19:1241-9.Chesnut III C.H., Skag A., Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently of fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004. 19:1241-9.De Laet C.E.D.H., van Hout B.A., Burger H. Et al. Incremental Cost of Medical Care after hip fracture and first vertebral fracture: The Rotterdam Study. Osteoporos Int. 1999.10: 66-72.De Laet C.E.D.H., van Hout B.A., Burger H. Et al. Incremental Cost of Medical Care after hip fracture and first vertebral fracture: The Rotterdam Study. Osteoporos Int. 1999.10: 66-72.Ensrud K, et al. Poster presented at: ECTS/IBMS; 25-29 June 2005; Geneva, Switzerland.Ensrud K, et al. Poster presented at: ECTS/IBMS; 25-29 June 2005; Geneva, Switzerland.Fleurence R.L., Iglesias C.P., Johnson J.M. The costeffectiveness of bisphosphonates for the prevention and treatment of osteoporosis. Pharmacoeconomics. 2007.25(11):913-933.Fleurence R.L., Iglesias C.P., Johnson J.M. The costeffectiveness of bisphosphonates for the prevention and treatment of osteoporosis. Pharmacoeconomics. 2007.25(11):913-933.Francis R.M. Oral bisphosphonates in the treatment of osteoporosis: a review. Current Ther Res. 1995. 56 (9):831-51.Francis R.M. Oral bisphosphonates in the treatment of osteoporosis: a review. Current Ther Res. 1995. 56 (9):831-51.Goettsch W,G., Penning F., Erkens J.E., et al. Persistent bisphosphonate usage reduces the risk of hospitalizations for osteoporotic fractures. J Bone Miner Res. 2005. 20 (Suppl 1):S278.Goettsch W,G., Penning F., Erkens J.E., et al. Persistent bisphosphonate usage reduces the risk of hospitalizations for osteoporotic fractures. J Bone Miner Res. 2005. 20 (Suppl 1):S278.International osteoporosis foundation. 2005. IOF adherence gap report. Accessed 10May 2010.www.osteofound. org/publications/pdf/adherence_gap_report.International osteoporosis foundation. 2005. IOF adherence gap report. Accessed 10May 2010.www.osteofound. org/publications/pdf/adherence_gap_report.IMS. Среднерозничные цены в рублях, 1H2010.IMS. Среднерозничные цены в рублях, 1H2010.Joness J., Scoot D. Cost-еffectivеness of alendronate for fracture prevention in postmenopausal women. Ashgate. 1999:1058-072.Joness J., Scoot D. Cost-еffectivеness of alendronate for fracture prevention in postmenopausal women. Ashgate. 1999:1058-072.Johnell O., Jonsson B., Jonsson l. et al. Cost effectiveness of alendronate (fosamax®) for the treatment of osteoporosis and prevention of fravtures. Pharmacoeconomics.2003.21(5):305-14.Johnell O., Jonsson B., Jonsson l. et al. Cost effectiveness of alendronate (fosamax®) for the treatment of osteoporosis and prevention of fravtures. Pharmacoeconomics.2003.21(5):305-14.Kanis J.A. Diagnosis of osteoporosis and assessment of fracture risk. Lancet.2002.359:929- 36.Kanis J.A. Diagnosis of osteoporosis and assessment of fracture risk. Lancet.2002.359:929- 36.Kothawala P., Badamgarav E., Ryu S., et al. Systematic review and meta-analyses of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007. 82 (12): 1493-1501.Kothawala P., Badamgarav E., Ryu S., et al. Systematic review and meta-analyses of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007. 82 (12): 1493-1501.Lucman S.P., Hughes D.E., Coxon F.P. et al. Nitrogencontaining bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res.1998. 13: 581-9.Lucman S.P., Hughes D.E., Coxon F.P. et al. Nitrogencontaining bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res.1998. 13: 581-9.Lin J.H., Chen I.W., Deluna F.A., et al. Role of calcium in plasma protein binding and renal handling of alendronate in hypo and hypercalcemic rats. J Pharmacol Exp Ther. 1993. 267:570-5.Lin J.H., Chen I.W., Deluna F.A., et al. Role of calcium in plasma protein binding and renal handling of alendronate in hypo and hypercalcemic rats. J Pharmacol Exp Ther. 1993. 267:570-5.Melton III L.J., Chrischilles E.A.,Cooper C., et al. Perspective: How many women have osteoporosis? J Bone Miner Res. 1992. 7:1005-10.Melton III L.J., Chrischilles E.A.,Cooper C., et al. Perspective: How many women have osteoporosis? J Bone Miner Res. 1992. 7:1005-10.National Osteoporosis Foundation. Osteoporosis: costeffectiveness analysis and review of the evidence for prevention, diagnosis and treatment. Osteoporos Int. 1998, 8 (Suppl.4): S1-S88.National Osteoporosis Foundation. Osteoporosis: costeffectiveness analysis and review of the evidence for prevention, diagnosis and treatment. Osteoporos Int. 1998, 8 (Suppl.4): S1-S88.Nguyen N.D., AhlborgY.G., Center J.R., et al. Residual lifetime risk of fractures in women and man. J. Bone Miner Res. 2007. 22:781-8.Nguyen N.D., AhlborgY.G., Center J.R., et al. Residual lifetime risk of fractures in women and man. J. Bone Miner Res. 2007. 22:781-8.Nelson B., Watts and Dima L. Diab. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrin Metab. 2010. 95(4); 0-0.Nelson B., Watts and Dima L. Diab. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrin Metab. 2010. 95(4); 0-0.Reginster L.Y., Burlet N. Osteoporosis: A still increasing prevalence. Bone. 2006. 38:S4-9Reginster L.Y., Burlet N. Osteoporosis: A still increasing prevalence. Bone. 2006. 38:S4-9Reginster J.Y., Rebenda V. Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin IntervAging. 2006. 1: 415-23.Reginster J.Y., Rebenda V. Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin IntervAging. 2006. 1: 415-23.Ridley A.J., Hall A. The small GTP-binding protein who regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell. 1992. 70:389-99.Ridley A.J., Hall A. The small GTP-binding protein who regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell. 1992. 70:389-99.Russel RG. Determination of structure function relationships among bisphosphonates. Bone. 2007.40(suppk2):S21-25.Russel RG. Determination of structure function relationships among bisphosphonates. Bone. 2007.40(suppk2):S21-25.Rizzoli R., Greenspan S.L., Bone G 3rd, et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res. 2002. 17:1988-96.Rizzoli R., Greenspan S.L., Bone G 3rd, et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res. 2002. 17:1988-96.Solomon D.H., Avom J., Katz J.N., et al. Compliance with osteoporosis medications. Arch Intern Med. 2005. 165(20): 2414-2419.Solomon D.H., Avom J., Katz J.N., et al. Compliance with osteoporosis medications. Arch Intern Med. 2005. 165(20): 2414-2419.Siris E.S., Harris S.T., Rosen C.L., et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertabral fractures from 2US claims databases. Mayo Clinic Proc. 2006. 81:1013-22.Siris E.S., Harris S.T., Rosen C.L., et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertabral fractures from 2US claims databases. Mayo Clinic Proc. 2006. 81:1013-22.Simon. J.A., Lewiecki E.M., Smith M.E., et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: multicenter, randomized, open-label, crossover study. Clin Ther. 2002. 24(11): 1871-86.Simon. J.A., Lewiecki E.M., Smith M.E., et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: multicenter, randomized, open-label, crossover study. Clin Ther. 2002. 24(11): 1871-86.Тosteson A.N., Melton L.J.3rd, Dawson-Hughes B. et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19(4); 437-447,Тosteson A.N., Melton L.J.3rd, Dawson-Hughes B. et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19(4); 437-447,
The authors declare that there are no conflicts of interest present.